Amgen Inc (MEX:AMG N) Stock Price, Trades & News

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Financial Strength

3/10

Name	Current	Vs Industry
Cash-To-Debt	0.21
Equity-to-Asset	0.1
Debt-to-Equity	6.24
Debt-to-EBITDA	3.44
Interest Coverage	3.93
Piotroski F-Score	8/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	1.99	Distress Grey Safe
Beneish M-Score	-2.61	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	11.7
	3-Year EBITDA Growth Rate	11.5
	3-Year EPS without NRI Growth Rate	7.3
	3-Year FCF Growth Rate	-2.7
	3-Year Book Growth Rate	32.8
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	3.89
	Future 3-5Y Total Revenue Growth Rate Estimate	2.58

Momentum Rank

8/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	79.39
	9-Day RSI	71.11
	14-Day RSI	66.55
	3-1 Month Momentum %	-7.32
	6-1 Month Momentum %	-1.3
	12-1 Month Momentum %	5.2

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.26
	Quick Ratio	1.01
	Cash Ratio	0.48
	Days Inventory	198.17
	Days Sales Outstanding	86.36
	Days Payable	83.77

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	2.8
	Dividend Payout Ratio	0.44
	3-Year Dividend Growth Rate	7.1
	Forward Dividend Yield %	2.79
	5-Year Yield-on-Cost %	4.19
	3-Year Average Share Buyback Ratio	-0.3
	Shareholder Yield %	4.82

Profitability Rank

10/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	68.26
	Operating Margin %	28.39
	Net Margin %	20.96
	EBITDA Margin %	44.79
	FCF Margin %	23.21
	OCF Margin %	28.97
	ROE %	94.89
	ROA %	8.66
	ROIC %	13.83
	3-Year ROIIC %	-3.33
	ROC (Joel Greenblatt) %	156.77
	ROCE %	17.59
	Years of Profitability over Past 10-Year	10
	Moat Score	8
	Tariff Resilience Score	7

GF Value Rank

7/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	26.04
	Forward PE Ratio	16.06
	PE Ratio without NRI	16.93
	Shiller PE Ratio	29.16
	Price-to-Owner-Earnings	21.86
	PEG Ratio	2.17
	PS Ratio	5.45
	PB Ratio	21.97
	Price-to-Free-Cash-Flow	23.59
	Price-to-Operating-Cash-Flow	18.86
	EV-to-EBIT	20.99
	EV-to-Forward-EBIT	17.25
	EV-to-EBITDA	14.83
	EV-to-Forward-EBITDA	14.57
	EV-to-Revenue	6.64
	EV-to-Forward-Revenue	6.57
	EV-to-FCF	28.76
	Price-to-GF-Value	1.06
	Price-to-Projected-FCF	1.73
	Price-to-DCF (Earnings Based)	1.28
	Price-to-DCF (FCF Based)	2.04
	Price-to-Median-PS-Value	1.01
	Price-to-Peter-Lynch-Fair-Value	1.81
	Earnings Yield (Greenblatt) %	4.76
	FCF Yield %	4.26
	Forward Rate of Return (Yacktman) %	13.49

Financials (Next Earnings Date:2026-08-05 Est.)

Annual Quarterly TTM

MEX:AMG N's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Amgen Inc Executives

Details

GF Value™: MXN5908.59

MEX:AMG N

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with AMG N. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil MXN)	682,618.554
	EPS (TTM) (MXN)	263.609
	Beta	-0.4662
	3-Year Sharpe Ratio	0.28
	3-Year Sortino Ratio	0.46
	Volatility %	25.31
	14-Day RSI	66.55
	14-Day ATR (MXN)	41.78477
	20-Day SMA (MXN)	6108.1365
	12-1 Month Momentum %	5.2
	52-Week Range (MXN)	5023 - 6718
	Shares Outstanding (Mil)	539.71

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	8
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Amgen Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Amgen Inc Stock Events

Financials Calendars

Event	Date	Price (MXN)
Third quarter earnings conference call for 2026	2026-11-04 13:30	In 124 days
Third quarter earnings results for 2026	2026-11-04	In 123 days
Second quarter earnings conference call for 2026	2026-08-05 13:30	In 33 days
Second quarter earnings results for 2026	2026-08-05	In 32 days
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-09 09:20	6,170.00 (+0.00%)
Jefferies Global Healthcare Conference	2026-06-04 09:55	5,858.00 (+0.00%)
General meeting for 2026	2026-05-19 11:00	5,670.00 (+0.00%)
USD 2.520000 Cash Dividend	2026-05-15	5,658.65 (+0.00%)
BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE	2026-05-13 10:00	5,658.65 (+0.00%)
First quarter earnings conference call for 2026	2026-04-30 16:30	5,900.00 (+0.00%)

Show

Entries

Amgen Inc Frequently Asked Questions

What is Amgen Inc(MEX:AMG N)'s stock price today?

The current price of MEX:AMG N is MXN6250.39. The 52 week high of MEX:AMG N is MXN6718.00 and 52 week low is MXN5023.00.

When is next earnings date of Amgen Inc(MEX:AMG N)?

The next earnings date of Amgen Inc(MEX:AMG N) is 2026-08-05 Est..

Does Amgen Inc(MEX:AMG N) pay dividends? If so, how much?

The Dividend Yield % of Amgen Inc(MEX:AMG N) is 2.8% (As of Today), Highest Dividend Payout Ratio of Amgen Inc(MEX:AMG N) was 0.46. The lowest was 0.34. And the median was 0.4. The Forward Dividend Yield % of Amgen Inc(MEX:AMG N) is 2.79%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
	AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS	2026-06-07
	AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE	2026-06-04
	AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026	2026-06-03
	AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE	2026-05-29
	Ember LifeSciences announces new strategic investments boosting Series A to $27M	2026-05-27
	AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH	2026-05-19
	Wall Street's Cardiac Bet: Where Diagnostics Meet the Money	2026-05-12
	/C O R R E C T I O N -- Amgen/	2026-04-30
	AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS	2026-04-30
	AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS	2026-04-24

10/Page

Articles on Amgen Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.